explore -WSS

explore

author：leisure time 2025-08-28 08:39:55 - browse：88

translucent 3D DNA helix with blue and purple background — Adobe

Verve Therapeutics said Monday that it had received clearance from the Food and Drug Administration to conduct a clinical trial in the U.S. of its experimental, gene-editing treatment for a common form of heart disease.

The FDA’s action removes a clinical hold on Verve’s CRISPR-based therapy, called VERVE-101, that was placed on it last November. Verve now intends to recruit participants from U.S. sites into a Phase 1 study that’s been underway since last year in New Zealand and the United Kingdom.

“We’re thrilled to get this clearance for VERVE-101,” said Verve CEO Sek Kathiresan. “Our study is called HEART-1 and our plan now is to activate U.S. sites.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Statins reduce cardiovascular risk in people living with HIV

entertainment

leisure time

WSS

Creating egg and sperm cells from stem cells raises ethical issues

Colonoscopy prep: Liquid

My chronic pain journey would have been easier knowing 5 things % STAT

Gene editing the human germline: What are the risks?

Argenx readies a blockbuster opportunity with drug for autoimmune disease

CVS Caremark has created a new ploy: the drug ‘rebate credit’

Wikipedia

explore

leisure time

ChatGPT in medicine: STAT answers readers' burning questions

Leading voice in opioid treatment defends methadone clinic system

At least 13 dead in Texas as scorching temps continue

4 missing after record

United colonoscopy coverage change 'may cost lives,' doctors say

How a key Senate committee is planning to regulate PBMs

Apple is now the first public company to be valued at $3 trillion

4 missing after record

Apple is now the first public company to be valued at $3 trillion

App could help diagnose ear infections more accurately — and at home

focus

UnitedHealth increases loan offers after Change Healthcare outage

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

Mike Pence ‘not interested in trading insults’ with Trump as he tries to win New Hampshire

Stop the failed accountable care organization experiment

Malaysia cuts short music fest after British band slams anti

Nurses recount patients attacks

entertainment

hotspot

leisure time

hotspot